Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 1799 易威. Please read: https://finlab.finance/en/setup?stock=1799

No install, open FinLab Studio

1799

易威 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

steady quality, premium valuation.

2 active signals
Revenue ≥20% Foreign buy
This page refreshes daily after the close. Add 易威 to your watchlist to track signal changes on your next visit.
Valuation 11Quality 61Growth 87Momentum 4Chips 92

Is 易威 a buy? Fundamentals and valuation first

  • Above-average profitability.Operating margin is in the 54th market percentile. Latest quarterly ROE ≈ 3.1%.

  • Valuation is high.PE is in the 91th market percentile.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 11.4% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 64.3%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20%, Foreign net buying 5 straight days are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.56
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 元大-金門 holds 412 lots
  • sellers have 134 lots left, ~100 sessions to clear

Window from 2026-01-17 · Price -10% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 元大-金門 has accumulated 412 lots since the start (sold 1%), still adding.
  • Main distributor 富邦-台北 peaked at 213 lots, has sold 77%, 49 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +1.04pp, mid holders +1, retail -0.60pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -85 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
元大-金門華南永昌-民權元大證券凱基-台北元富-林園元大-板橋
Distributing
富邦-台北中國信託-忠孝群益金鼎-三民摩根大通永豐金-永康華南永昌-嘉義
Desks
own scale
元大-六合元大-善化元大-土城凱基-中港
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 元大-金門 +412
    sold 1%· still adding
  • 華南永昌-民權 +290
    sold 10%
  • 元大證券 +222
    sold 9%
  • 凱基-台北 +199
    sold 5%· still adding
  • 元富-林園 +134
    sold 0%
  • 元大-板橋 +118
    sold 0%

Distributing

  • 富邦-台北 49 left
    sold 77%· paused recently
  • 中國信託-忠孝 45 left
    sold 30%· ~28 sessions to clear
  • 群益金鼎-三民 4 left
    sold 90%· paused recently
  • 摩根大通 13 left
    sold 68%· ~7 sessions to clear
  • 永豐金-永康 7 left
    sold 78%· paused recently
  • 華南永昌-嘉義 8 left
    sold 74%· paused recently

Desks

  • 元大-六合 -534
    unclassified
  • 元大-善化 -290
    unclassified
  • 元大-土城 -195
    unclassified
  • 凱基-中港 -185
    unclassified
Still selling 134 lots ~100 sessions to bottom at most
Recent buy/sell force +372 absorbed / -63 sold buyers slightly ahead
Hedge-desk net short -19 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 64.3%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

94 historical occurrences (since 2008-11-10)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 47.8%, Sample 90, Median -0.36%, Excess +1.1%, Beat mkt rate 42.2%；60-day: Win 54.5%, Sample 88, Median +2.71%, Excess +3.51%, Beat mkt rate 43.2%；120-day: Win 48.8%, Sample 86, Median -0.14%, Excess +10.4%, Beat mkt rate 39.5%

120 days after: historical avg +18.27%

20-day +2.24%
60-day +7.21%
120-day +18.27%
20-day
60-day
120-day
Win
47.8%
54.5%
48.8%
Sample
90
88
86
Median
-0.36%
+2.71%
-0.14%
Excess
+1.1%
+3.51%
+10.4%
Beat mkt rate
42.2%
43.2%
39.5%

Over 86 occurrences, 120-day forward avg gained 18.27%, beat the market by 10.4 pts; win rate 48.8%.

Foreign net buying for 5 straight days

Active · now 6%

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

26 historical occurrences (since 2013-10-03)
Average forward return after Foreign net buying for 5 straight days。20-day: Win 52%, Sample 25, Median +0.27%, Excess +1.06%, Beat mkt rate 40%；60-day: Win 36%, Sample 25, Median -1.63%, Excess -7.59%, Beat mkt rate 28%；120-day: Win 27.3%, Sample 22, Median -10.08%, Excess -2.86%, Beat mkt rate 18.2%

120 days after: historical avg +5.45%

20-day +3.47%
60-day -1.76%
120-day +5.45%
20-day
60-day
120-day
Win
52%
36%
27.3%
Sample
25
25
22
Median
+0.27%
-1.63%
-10.08%
Excess
+1.06%
-7.59%
-2.86%
Beat mkt rate
40%
28%
18.2%

Over 22 occurrences, 120-day forward avg gained 5.45%, lagged the market by 2.86 pts; win rate 27.3%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

21 times historically; 60-day forward avg +20.35%, win rate 57.1%, beating the market by +13.29 pts on average.

What does 易威 do? Company profile

生技醫療業；製藥、困難學名藥、505(b)(2)新劑型藥物與CDMO 上櫃

Overview

1799 對應易威生醫科技股份有限公司，為櫃買中心上櫃普通股，非ETF、ETN、權證或特別股。公司成立於1998年8月10日，前身為紅電醫學科技股份有限公司，2015年更名為易威生醫科技股份有限公司；2008年11月10日上櫃。總部位於新竹市科學園區研發二路10號1樓。董事長為林翰飛，並兼任執行長；總經理為李艾平；發言人為吳雪君。依公開資料，實收資本額約新台幣12.47億元，已發行普通股約124,689,527股。114年度年報揭露，易威生醫含總公司、子公司華瀚及Tulex，2025年員工數84人，其中研發31人、行銷業務11人、製造及品保20人、管理及財務22人；員工分布為總公司17.86%、華瀚32.14%、Tulex 50.00%。主要股東依2025年4月28日官方前十大股東資料包括中華世紀投資28,666,945股、22.99%；Eternity Asia Limited 6,985,306股、5.60%；生達化學製藥6,794,600股、5.45%；台瀚科技5,094,600股、4.09%；富邦綜合證券受託保管X＆Z能源投資公司投資專戶3,892,018股、3.12%；Bayberry Management LLC 3,841,600股、3.08%；林翰飛3,255,713股、2.61%；蔡瑞聰3,202,000股、2.57%；曾振源2,248,554股、1.80%；李世仁1,873,723股、1.50%。

Business

易威已由早期體溫量測醫療產品轉型為以藥物開發、生產與銷售為核心的生技製藥公司。主要營運平台包括美國子公司Magnifica與Tulex Pharmaceuticals；Magnifica聚焦原料藥、Rx-to-OTC與新劑型藥物開發，Tulex專注高門檻困難學名藥、505(b)(2)新劑型藥物及美國cGMP製造。商業模式包含自有困難學名藥上市銷售、505(b)(2)共同開發、CDMO委託開發與生產、里程碑收入、產品上市後銷售分潤，以及中國市場代理銷售。114年度合併營收597,410仟元，年增10.54%；銷售地區比重為中國大陸361,816仟元、60.57%，美國235,150仟元、39.36%，台灣444仟元、0.07%。已成功或已取得藥證的產品包括TLX-001長效型咳嗽藥、TLX-005膀胱過動症用藥、TLX-004長效型抗憂鬱藥物、TLX-007抗憂鬱症藥物、TLX-015預防及治療產後出血藥物、TLX-018治療出血藥物、TLX-030抗發炎藥物、TLX-047減輕發炎性藥物、TLX-024液態口服劑型癲癇505(b)(2)新藥，以及中國NMPA核准的HH-001沙庫巴曲纈沙坦鈉片。公司與跨國藥廠及美國通路商合作，Tulex曾與Eton Pharmaceuticals合作505(b)(2)液態口服劑型藥品，由Tulex負責開發與生產、合作方負責開發費用與藥證/銷售權，易威收取里程碑並分享產品利潤。主要客戶與供應商在年報中以甲、乙匿名揭露：2025年最大供應商占進貨61.31%，第二供應商占10.24%；最大及第二大銷售客戶各占銷貨約13.79%與13.78%。

Outlook 2025–2028

2025至2028年核心展望可分為三條主線。第一，美國市場方面，既有困難學名藥與505(b)(2)品項已進入較密集取證與上市期；公司114年度年報稱截至2025年底已有8項困難學名藥與1項505(b)(2)新藥取得美國FDA藥證，並在美國紐澤西cGMP廠生產及透過美國通路商銷售，後續成長取決於產品鋪貨速度、通路拉貨、CDMO開發案里程碑與上市後分潤。第二，中國市場方面，HH-001沙庫巴曲纈沙坦鈉片於2023年10月取得NMPA藥證，2024年4月正式銷售，2025年銷售量為2024年的兩倍；公司策略是採輕資產模式，與當地原料藥供應商、GMP生產廠合作，並自行建構銷售團隊以代理模式拓展醫療體系通路。第三，策略整合方面，易威於2026年3月宣布以股份轉換方式併購健亞，換股完成後健亞將成為易威100%子公司並終止上櫃；若如期完成，將結合健亞台灣研發製造與易威美國產品開發/商業化能力，擴大台灣製造、美國市場與亞洲法規開發能量。主要成長動能包括全球人口高齡化、健保控費推升學名藥與高門檻劑型需求、兒童特殊液態劑型需求、美國505(b)(2)市場、CDMO收入成長及中國HH-001滲透率提升。主要風險包括藥證審查時程不確定、研發失敗、學名藥競爭加劇、價格與集採壓力、HH-001涉及原廠專利/授權及中國醫藥政策風險、主要供應商集中、主要客戶匿名且集中度仍需追蹤、匯率波動、健亞整合案能否取得主管機關核准及整合綜效能否落實。2027至2028年的量化營收與獲利未見公司正式可查證指引，故不推估具體數字。

Supply Chain

Upstream
  • 原料藥供應商甲 年報匿名揭露之最大供應商，2025年占進貨淨額61.31%；公司未揭露正式名稱，無法確認是否為台股掛牌公司。
  • 原料藥供應商乙 年報匿名揭露之第二大供應商，2025年占進貨淨額10.24%；公司未揭露正式名稱，無法確認是否為台股掛牌公司。
  • 中國大陸GMP生產廠與當地原料藥供應商 易威於中國市場採輕資產模式，與當地上游原料藥供應商及GMP生產廠合作；具體公司名稱未揭露。
  • Tulex Pharmaceuticals Inc. 易威美國子公司/孫公司體系，負責高門檻困難學名藥、505(b)(2)藥品開發與美國紐澤西cGMP製造；非台股掛牌。
  • Magnifica Inc. 易威美國子公司，主要負責API銷售、Rx-to-OTC與新劑型藥物開發；非台股掛牌。
Downstream
  • 美國通路商 易威FDA核准產品透過美國合作夥伴既有學名藥銷售通路進行銷售；年報未揭露具體名稱。
  • Eton Pharmaceuticals, Inc. 美國NASDAQ上市藥廠，與Tulex合作505(b)(2)液態口服劑型藥品；由Eton負責開發費用、藥證申請與上市銷售權，非台股掛牌。
  • 江蘇華瀚醫藥科技有限公司 易威投資之中國市場開發與銷售平台，負責大陸市場拓展，HH-001已於中國銷售；非台股掛牌。
  • 健亞生物科技股份有限公司 4130 2026年3月易威宣布以股份轉換方式取得健亞100%股權；健亞具台灣研發、製造、亞洲及澳洲臨床法規經驗與CDMO能力，若交易完成將成為下游/製造及市場整合夥伴。
  • 中國大陸醫療體系與醫院通路 HH-001銷售已拓展中國大陸多省醫療體系，公開新聞稱已開發逾1萬家醫院通路；屬終端通路/醫療院所，非台股掛牌。

Competitors

Sources（11）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.